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SOX9 is a transcription factor that plays a key role in
chondrogenesis. Aggrecan is one of the major structural
components in cartilage; however, the molecular mecha-
nism of aggrecan gene regulation has not yet been fully
elucidated. TC6 is a clonal chondrocytic cell line derived
from articular cartilage. The purpose of this study was to
examine whether SOX9 modulates aggrecan gene expres-
sion and to further identify molecules that regulate Sox9
expression in TC6 cells. SOX9 overexpression in TC6 cells
enhanced by ;3-fold the transcriptional activity of the
AgCAT-8 construct containing 8-kilobase (kb) promoter/
first exon/first intron fragments of the aggrecan gene.
SOX9 enhancement of aggrecan promoter activity was
lost when we deleted a 4.5-kb fragment from the 3*-end of
the 8-kb fragment corresponding to the region including
the first intron. In TC6 cells, SOX9 enhanced the tran-
scriptional activity of a reporter construct containing the
Sry/Sox consensus sequence >10-fold. SOX9 enhancement
of aggrecan gene promoter activity and SOX9 transacti-
vation through the Sry/Sox consensus sequence were not
observed in osteoblastic osteosarcoma cells (ROS17/2.8),
indicating the dependence on the cellular background.
Northern blot analysis indicated that TC6 cells constitu-
tively express Sox9 mRNA at relatively low levels. To ex-
amine regulation of Sox9 gene expression, we investi-
gated the effects of calciotropic hormones and cytokines.
Among these, retinoic acid (RA) specifically enhanced
Sox9 mRNA expression in TC6 cells. The basal levels of
Sox9 expression and its enhancement by RA were ob-
served similarly at both permissive (33 °C) and nonper-
missive (39 °C) temperatures. Furthermore, RA treatment
enhanced the transcriptional activity of a reporter con-
struct containing the Sry/Sox consensus sequence in TC6
cells. Moreover, RA treatment also enhanced the tran-
scriptional activity of another reporter construct contain-
ing the enhancer region of the type II procollagen gene in
TC6 cells. These observations indicate that SOX9 en-
hances aggrecan promoter activity and that its expres-
sion is up-regulated by RA in TC6 cells.
Sox9 is a member of the family of Sox (Sry-type high mobility
group box) genes that were first identified on the basis of a
region with high homology to that of Sry (sex-determining
region Y) (1). This region encodes a 79-amino acid motif that is
known as a high mobility group box and is responsible for
sequence-specific binding to DNA (2, 3). Several high mobility
group box proteins are known to act as transcription factors (4),
and some of the Sox genes have been shown to be expressed in
a tissue-specific manner during development. SOX9 is ex-
pressed predominantly in cells in mesenchymal condensations
during the early development of skeletons in embryos (5).
These SOX9-expressing regions coincide with those where dep-
osition of cartilage matrix takes place, suggesting a role for
SOX9 in skeletal formation (6–8). In addition, mutations in
human SOX9 have been observed in patients with campomelic
dysplasia that is characterized by the presence of skeletal
malformation and XY sex reversal (9, 10). In mouse chimeras,
SOX92/2 cells are excluded from all cartilaginous tissues dur-
ing embryonic development and are present in juxtaposed mes-
enchyme that does not express chondrocyte-specific markers
such as procollagen types II, IX, and XI and aggrecan (11).
These observations indicate that SOX9 plays a key role in
chondrogenesis and skeletogenesis.
Aggrecan, a large chondroitin sulfate proteoglycan, is one of
the major structural components in cartilage matrix (12). Mice
with a phenotype known as cartilage matrix deficiency (Cmd)
have been found to possess an autosomal recessive mutation in
the aggrecan gene. These mice exhibit cleft palate and short
limbs, tail, and snout, whereas their levels of type II collagen
and link protein are normal (13). The presence of the mutation
in the aggrecan gene in the Cmd mice confirms the critical role
of aggrecan in cartilage formation; however, the molecular
mechanism of aggrecan gene regulation has not yet been fully
elucidated.
TC6 cells are derived from articular cartilage of transgenic
mice harboring a temperature-sensitive simian virus 40 large
T-antigen gene (14). TC6 cells express mRNAs of the genes
encoding cartilage phenotype-related proteins such as type II
procollagen, link protein, and aggrecan.
The purpose of this study was to examine the effects of SOX9
on the aggrecan gene promoter/enhancer and regulation of
Sox9 gene expression in TC6 cells. We found that SOX9 en-
hances the promoter/enhancer activity of the aggrecan gene in
TC6 cells. Furthermore, we also found that SOX9 expression is
enhanced by RA1 in TC6 cells.
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MATERIALS AND METHODS
Cell Culture—TC6 cells were cultured at 33 °C in a-modified Eagle’s
medium (a-MEM; Sigma) supplemented with 0.5% fetal bovine serum
(FBS; Life Technologies, Inc.) (14). For temperature shift experiments,
TC6 cells were cultured at 39 °C. ROS17/2.8 cells were cultured at 37 °C
in modified Ham’s F-12 medium (Life Technologies, Inc.) supplemented
with 5% FBS (15). Primary chondrocytes were prepared from rib carti-
lage of newborn ICR mice (16). Chondrocytes were isolated from rib
cage cartilage by digestion in 3 mg/ml collagenase (Sigma) for 30 min
and then by further digestion in 3 mg/ml collagenase for 5 h. Primary
osteoblasts were isolated from newborn ICR mouse calvariae by five
sequential enzymatic digestions using 1 mg/ml collagenase and 250
units/ml Dispase (Godo Shusei, Tokyo, Japan) (17). The cells in the last
three fractions were pooled. Primary fibroblasts were prepared from
adult ICR mouse peritoneum. Peritoneum was incubated in 1 mg/ml
collagenase and 250 units/ml Dispase for 1 h. Primary chondrocytes
were cultured in Dulbecco’s modified Eagle’s medium (Life Technolo-
gies, Inc.), and primary osteoblasts and primary fibroblasts were cul-
tured in a-MEM supplemented with 10% FBS and antibiotics (100
units/ml penicillin G sodium, 100 mg/ml streptomycin sulfate, and 0.25
mg/ml amphotericin B) at 37 °C.
Chloramphenicol Acetyltransferase (CAT) Assay—CAT assay was
performed as described previously (18). TC6 cells were plated in six-well
cluster plates (35-mm well diameter) at 6–7 3 104 cells/cm2. One day
later, TC6 cells were cotransfected with 1 mg of CAT reporter plasmids
and a SOX9 expression plasmid containing a 1.9-kb Sox9 cDNA insert
(5) or a pSG5 vector plasmid as a negative control. The reporter con-
structs AgCAT-8, AgCAT-5, and AgCAT-6, containing 8-, 3.5-, and
1.1-kb promoter/first exon (encoding the 59-untranslated region)/first
intron fragments of the mouse aggrecan gene, respectively (19), were
used. TC6 cells were also transfected with 1 mg of pCII4-C reporter
plasmid containing a 1.6-kb intron fragment of the murine type II
procollagen gene (20). In some experiments, the cells were cultured in
the presence or absence of 1 mM RA after transfection. Transfection was
performed using LipofectAMINE (Life Technologies, Inc.) to form DNA-
lipid complexes (21). TC6 cells were exposed to the DNA solution for 3 h
without FBS, and then the cells were cultured in a-MEM supplemented
with 0.5% FBS. ROS17/2.8 cells were subjected to transfection with the
SOX9 expression vector in combination with reporter plasmids as de-
scribed above. The cells were harvested 72 h after transfection. Cell
extracts were prepared and used for the analysis of CAT activity.
Protein concentrations in the cell lysates were determined according to
the Coomassie Brilliant Blue G method as described (22). Equivalent
amounts of the cellular proteins were incubated for 2 h at 37 °C in
reaction buffer containing 0.25 M Tris-HCl (pH 7.5), 40 mM acetyl-CoA
(Sigma), and [14C]chloramphenicol (Amersham Pharmacia Biotech).
The levels of acetylation were estimated by TLC followed by autora-
diography of the TLC plates. Quantitation of the acetylation levels was
performed using a BAS 2000 bioimaging analyzer system (Fuji Film
Inc., Tokyo). The effect of Sox9 promoter activity was estimated by
measuring the conversion rate. Experiments were repeated two or three
times in triplicate with independent preparations of cell extracts. To
monitor transfection efficiency, CAT activity was normalized against
the luciferase (LUC) activity of the pGL2-Control-LUC construct co-
transfected with the reporter plasmids and SOX9 expression plasmid in
part of the experiments. Such experiments gave results similar to those
in which CAT activity was normalized against total protein contents.
Luciferase Assay—Transfection experiments were conducted as de-
scribed above. The SOX9 effect on promoter activity was examined by
measuring luciferase activity using a control empty vector plasmid
(pSG5) as a reference. Luciferase assay was performed as described
previously (23) using a Picagene kit (Tokyo Ink Co., Tokyo) and a
luminometer (Berthold Autolumat LB953). TC6 cells were cotrans-
fected with 1 mg of LUC reporter construct that carries four tandem
copies of the 30-mer (GATCAGACTGAGAACAAAGCGCTCTCACAC)
derived from the enhancer region of CD3-e (24) containing the Sry/Sox
FIG. 1. SOX9 enhances the tran-
scriptional activity of the aggrecan
gene via the enhancer region within
the first intron in TC6 cells. A, sche-
matic illustration of the constructs of the
aggrecan gene fragments linked to the
CAT reporter gene. The AgCAT-8, Ag-
CAT-5, and AgCAT-6 constructs contain
8-, 3.5-, and 1.1-kb aggrecan gene frag-
ments, respectively. Black boxes indicate
exons. B, SOX9 activation of the aggre-
can-CAT reporter gene constructs in TC6
cells (upper panel); ROS17/2.8 cells (mid-
dle panel); and primary chondrocytes, pri-
mary osteoblasts, and primary fibroblasts
(lower panel). These cells were cotrans-
fected with 1 mg of reporter constructs
and 1 mg of SOX9 expression vector or 1
mg of empty pSG5 vector. Transfected
cells were incubated for 72 h, and CAT
activity was determined as described un-
der “Materials and Methods.” Experi-
ments were repeated three times (upper
and middle panels) or twice (bottom
panel) in triplicate with independent
preparations of cell extracts. The repre-
sentative data are shown. Data are pre-
sented as means 6 S.D. (n 5 3). *, p ,
0.01; **, p , 0.05 by unpaired Student’s t
test.
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consensus sequence (AACAAAG) and the SOX9 expression vector or
pSG5 vector plasmid. LUC activity was normalized against the total
protein concentration measured by the Coomassie Brilliant Blue G
method (22). In part of the experiments, the pSV2-CAT construct was
cotransfected with LUC constructs to monitor transfection efficiency.
These experiments gave results similar to those in which LUC activity
was normalized against total protein contents. pGL2-Control-LUC
(Promega) was used as a control.
Northern Blot Analysis—Total cellular RNA was prepared according
to the acid/guanidium thiocyanate/phenol/chloroform method (25). Ali-
quots of 10 mg of the total RNA/lane were electrophoresed on 1.0%
agarose gels containing 0.66 M formaldehyde and transferred to nylon
filters (Hybond-N, Amersham Pharmacia Biotech) by electroblotting.
Filters were prehybridized for 24 h at 42 °C. A 1.6-kb EcoRI-BglII
fragment of the mouse Sox9 cDNA was used as a probe (5). A rat
liver/bone/kidney-type alkaline phosphatase probe (0.6 kb) was pre-
pared by digestion with EcoRI (26). A 1.2-kb EcoRI fragment of the
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) probe was used
as a control. Each cDNA was labeled using the BcaBEST random
primer labeling kit (Takara Shuzo Co., Ltd., Tokyo) and [a-32P]dCTP
(NEN Life Science Products). Hybridization was performed at 42 °C for
24 h. Filters were washed in 23 SSC and 0.5% SDS for 20 min at room
temperature and in 0.23 SSC and 0.5% SDS for 20 min at 65 °C. Filters
were then exposed to x-ray films using intensifying screens at 280 °C.
Growth Rate Evaluation—TC6 cells were seeded into four-well plates
(2 cm2/well) and cultured in a-MEM supplemented with 0.5% FBS in
the absence or presence of RA. At the indicated time points, the cells
were trypsinized and counted using a Coulter counter.
Statistical Analysis—Statistical evaluations of the data were con-
ducted using unpaired Student’s t test. Data are presented as means 6
S.D. p values ,0.05 were considered to be statistically significant.
RESULTS
SOX9 Enhances the Transcriptional Activity of the Aggrecan
Gene Promoter/Enhancer in TC6 Cells—To examine whether
SOX9 regulates the transcriptional activity of the aggrecan
gene, a CAT reporter gene construct (AgCAT-8) containing an
8-kb mouse aggrecan gene fragment that includes the aggrecan
gene promoter, the first exon, and part of the first intron (Fig.
1A) was cotransfected (19) with a SOX9 expression vector into
TC6 cells. SOX9 overexpression enhanced the transcriptional
activity of the AgCAT-8 construct ;3-fold (Fig. 1B, upper pan-
el). To further determine whether any particular region within
the 8-kb aggrecan gene fragment responds to SOX9 overexpres-
sion, we also examined the CAT activities of the two deletion
constructs AgCAT-5 (3.5 kb) and AgCAT-6 (1.1 kb) (Fig. 1A).
SOX9 enhancement was no longer observed when we deleted
a 4.5-kb intron fragment from the 39-end of the 8-kb frag-
ment corresponding to the region including the first intron
FIG. 2. SOX9 transactivates via the Sry/Sox consensus sequence in TC6 cells, but not in ROS17/2.8 cells. SOX9 modulation of the
transcriptional activity of the AACAAAG concatamer-LUC reporter gene construct was examined. TC6 and ROS17/2.8 cells were cotransfected
with 1 mg of reporter plasmid and 1 mg of SOX9 expression plasmid or 1 mg of empty pSG5 vector. The reporter plasmid carries four copies of the
30-mers containing AACAAAG. Experiments were repeated twice using six independently transfected cultures each time. Representative data are
shown. Data are presented as means 6 S.D. (n 5 6). *, p , 0.01 by unpaired Student’s t test.
FIG. 3. Sox9 mRNA is constitutively expressed and is up-regu-
lated by RA in TC6 cells. Confluent TC6 cells were cultured for 48 h
in the absence (control) or presence of 4 ng/ml transforming growth
factor b1 (TGF-b1), 10 ng/ml insulin-like growth factor (IGF), 10 ng/ml
interleukin-1b (IL-1b), 100 nM vitamin D (Vit. D), 100 nM parathyroid
hormone (PTH), and 1 mM RA. Total RNA was isolated and subjected to
Northern blot analysis as described under “Materials and Methods.”
The positions of Sox9, GAPDH, and 18 S and 28 S ribosomal RNAs are
indicated. Experiments were repeated twice, and representative data
are shown.
FIG. 4. Dose and time effect of RA on Sox9 mRNA expression in
TC6 cells. A, dose dependence of RA effect on the expression of Sox9
mRNA. Confluent TC6 cells were treated with the indicated doses of RA
for 48 h. B, time course of RA effect on the expression of Sox9 mRNA.
Confluent TC6 cells were cultured for the indicated hours in the ab-
sence (2) or presence (1) of 1 mM RA. Total RNA was prepared and
subjected to Northern blot analysis as described under “Materials and
Methods.” The positions of Sox9, GAPDH, and 18 S and 28 S ribosomal
RNAs are indicated. Experiments were repeated twice, and represent-
ative data are shown.
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(AgCAT-5) (Fig. 1B, upper panel), indicating that the 4.5-kb
first intron fragment plays a major role in mediating the tran-
scriptional activation effect of SOX9 on the aggrecan gene in
TC6 cells. SOX9 reduced CAT activities by ;30% when both
the promoter and intron were deleted (AgCAT-6) (Fig. 1B,
upper panel).
As SOX9 is expressed specifically in cartilage but not in
bone, it may require certain transcription factors or cofactors
pertinent to a specific cellular background to enhance the 8-kb
aggrecan gene fragment. To test this point, the AgCAT-8, Ag-
CAT-5, and AgCAT-6 constructs were cotransfected with the
SOX9 expression vector into osteoblast-like ROS17/2.8 cells.
SOX9 overexpression decreased the transcriptional activity of
the AgCAT-8 construct by ;80% in ROS17/2.8 cells. SOX9
suppression of the transcriptional activity of AgCAT-8 was lost
when the 4.5-kb intron region was deleted (AgCAT-6 and Ag-
CAT-5) (Fig. 1B, middle panel). Thus, SOX9 enhancement of
aggrecan gene promoter activity was observed in TC6 cells, but
not in ROS17/2.8 cells.
To compare SOX9 effects on AgCAT-8 activity in primary
cultures of chondrocytes versus those in TC6 cells, we carried
out experiments using primary chondrocytes prepared from
ribs of newborn mice (16), primary osteoblasts prepared from
calvariae of newborn mouse (17), and primary fibroblasts from
adult mice. In contrast to the SOX9 enhancement of AgCAT-8
activities in TC6 cells, SOX9 suppressed AgCAT-8 activity in
primary chondrocytes slightly (by 20%), although the effects
were statistically significant (p , 0.05) and reproducible in two
independent experiments (Fig. 1B, lower panel). In primary
cultures of osteoblasts and fibroblasts, SOX9 affected AgCAT-8
activity slightly again (with 10–20% suppression) in a similar
direction as seen in primary chondrocytes, although these
SOX9 effects in primary osteoblasts and fibroblasts were not
statistically significant in both of the two independent experi-
ments (Fig. 1B, lower panel).
SOX9 Activates Transcriptional Activity via the Sry/Sox
Consensus Sequence in TC6 Cells—SOX9 has been shown to
enhance transcriptional activity via the Sry/Sox consensus
sequence (6, 7, 27). However, it was not known whether the
SOX9 activation of transcription via such consensus sequences
could also be affected by the cellular background. To address
this issue, the LUC reporter construct that carries four tandem
copies of a 30-mer containing the Sry/Sox consensus sequence
(AACAAAG) was cotransfected with the SOX9 expression vec-
tor into TC6 cells (24). SOX9 overexpression enhanced the
transcriptional activity of the LUC reporter construct contain-
ing the Sry/Sox consensus sequence .10-fold in TC6 cells (Fig.
2). To examine SOX9 enhancement of transcriptional activity
via the Sry/Sox consensus sequence in another cellular back-
ground, the LUC reporter construct containing the Sry/Sox
consensus sequence was cotransfected with the SOX9 expres-
sion vector into ROS17/2.8 cells. The transcriptional activity of
the Sry/Sox consensus sequence was not enhanced by SOX9 in
ROS17/2.8 cells (Fig. 2).
Sox9 mRNA Expression and Its Up-regulation by RA in TC6
Cells—We next examined the endogenous levels of SOX9 ex-
pression in TC6 cells. As shown in Fig. 3, Sox9 mRNA was
expressed, although at relatively low levels, in TC6 cells. To
investigate the regulation of Sox9 mRNA expression, we exam-
ined the effect of calciotropic hormones and cytokines. The Sox9
mRNA level was not affected by 48-h treatment with 4 ng/ml
transforming growth factor b1, 10 ng/ml insulin-like growth
factor, 10 ng/ml interleukin-1b, 100 nM vitamin D, or 100 nM
parathyroid hormone. However, 1 mM RA specifically up-regu-
lated Sox9 mRNA expression in TC6 cells (Fig. 3). GAPDH
mRNA levels (serving as a control) were not altered by RA,
suggesting the specificity of the RA effects on Sox9 gene ex-
pression in TC6 cells.
The dose dependence of the RA effect on Sox9 mRNA expres-
sion in TC6 cells was examined at 0.01, 0.1, and 1 mM. The
effect of 48 h of treatment with 1 mM RA on Sox9 mRNA
expression was investigated (Fig. 4). Again, RA at 1 mM did not
affect GAPDH expression, indicating the specificity of the RA
effect on Sox9 gene expression.
Temperature Shift Effect on Sox9 mRNA Expression in Re-
sponse to RA in TC6 Cells—TC6 cells are derived from articular
cartilage of transgenic mice harboring the temperature-sensi-
tive mutant tsA58 SV40 large T-antigen gene (14). Therefore,
we examined the effect of temperature shift on Sox9 mRNA
expression in response to RA in TC6 cells. As shown in Fig. 5,
the basal levels of Sox9 mRNA expression were similar regard-
less of temperature (33 °C (permissive) and 39 °C (nonpermis-
sive)) in TC6 cells. Furthermore, treatment with RA enhanced
Sox9 mRNA expression at 39 °C similarly to treatment at 33 °C
(Fig. 5). These results indicate that the basal levels of SOX9
expression and the RA effects on its expression are similar
between 33 and 39 °C.
RA Suppresses the Transcriptional Activity of the Aggrecan
Gene Promoter/Enhancer in TC6 Cells—As SOX9 activates the
8-kb aggrecan gene fragment and RA enhances Sox9 gene
expression in TC6 cells, we wished to test whether RA en-
hances the transcriptional activity of the 8-kb aggrecan gene
fragment. Contrary to our prediction, RA suppressed the tran-
scriptional activity of AgCAT-8 by ;70%, although this was
statistically not significant (p 5 0.055). This suggests the par-
allel presence of RA-dependent suppressive pathway(s) that
could overcome the RA-activated SOX9 activity on AgCAT-8
(Fig. 6).
RA Transactivates Gene Expression via the Sry/Sox Consen-
sus Sequence in TC6 Cells—As the entire 8-kb aggrecan gene
fragment could be regulated by many pathways or transcrip-
tion factors other than SOX9, we tested whether at least the
Sry/Sox consensus sequence could be activated by RA in TC6
cells. To examine whether RA enhances the transcriptional
activity if only Sry/Sox consensus sequences are linked to the
reporter gene in TC6 cells, we used the LUC reporter construct
that carries four tandem copies of the 30-mer containing the
AACAAAG consensus motif as described above. Treatment
FIG. 5. Temperature shift effect on Sox9 mRNA expression in
response to RA in TC6 cells. TC6 cells were plated at 105/cm2 and
cultured at 33 °C for 24 h. Subsequently, TC6 cells were cultured for
48 h in the absence or presence of 1 mM RA at 33 or 39 °C. Total RNA
was prepared and subjected to Northern blot analysis as described
under “Materials and Methods.” Quantitation was carried out using a
densitometer, and the ratios of Sox9 to GAPDH are indicated. Data
represent one of two independent experiments with similar results.
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with RA at 1 mM enhanced by 12-fold the transcriptional activ-
ity of the LUC reporter construct containing the Sry/Sox con-
sensus sequence (Fig. 7).
RA Enhances the Transcriptional Activity of the Type II
Procollagen Gene in TC6 Cells—As we observed that SOX9
activated the transcriptional activity of the aggrecan gene pro-
moter/enhancer in TC6 cells, we wished to test whether any
other gene fragment that has been well characterized can re-
spond to SOX9. Among the genes encoding cartilage-specific
molecules, SOX9 is known to enhance type II procollagen en-
hancer activity in chondrocytes (6, 7, 27). Therefore, we exam-
ined whether RA enhances type II procollagen enhancer activ-
ity. In TC6 cells, treatment with RA at 1 mM enhanced the
activity of the pCII4-C-CAT (Col2-CAT) reporter construct con-
taining a 1.6-kb intron fragment of the murine type II procol-
lagen gene where the chondrocyte-specific Sry/Sox consensus
sequence has been located (28) (Fig. 8). RA did not alter the
activity of pSV2-CAT, indicating the specificity of its effect on
the type II procollagen enhancer.
RA Suppresses Proliferation of TC6 Cells—As agents acting
on the expression of the differentiation-related phenotype could
reciprocally regulate proliferation, we examined the effect of
RA on the proliferation of TC6 cells. The cells were cultured in
the absence or presence of 1 mM RA for 1, 2, and 3 days. RA
reduced TC6 cell numbers by 22% on day 2 and by 40% on day
3 (Fig. 9A). RA-mediated reduction of TC6 cell proliferation was
observed in a dose-dependent manner after 3 days of treatment
(Fig. 9B).
SOX9 Does Not Affect Alkaline Phosphatase Expression in
ROS17/2.8 Cells and Primary Osteoblasts—To further exam-
ine the specificity of SOX9 action in chondrocytes, SOX9 was
overexpressed in ROS17/2.8 cells and primary osteoblasts to
see its effect on alkaline phosphatase mRNA expression. En-
dogenous levels of SOX9 were not detectable in these cells.
SOX9 overexpression was confirmed by the presence of the
Sox9 mRNA band (Fig. 10), but it did not affect alkaline phos-
phatase mRNA expression in both ROS17/2.8 cells and primary
osteoblasts. GAPDH mRNA levels served as a control and were
not affected by SOX9 overexpression.
DISCUSSION
We demonstrate here that SOX9 enhances the transcrip-
tional activity of the 8-kb fragment of the aggrecan gene. Bi et
al. (11) reported that SOX92/2 cells do not express aggrecan in
mouse chimeras, suggesting that SOX9 activates aggrecan
gene expression in vivo as well. SOX9 has been shown to bind
to chondrocyte-specific enhancer sequences in the first intron of
the murine type II procollagen gene (6, 27) as well as the
murine type XI procollagen gene (29) to activate transcription
of these genes through these enhancers. Our observation pre-
FIG. 6. RA suppresses the transcriptional activity of the 8-kb aggrecan gene promoter/enhancer in TC6 cells. The transcriptional
activities of the AgCAT-8 reporter construct containing 8-kb promoter/first exon/first intron fragments of the aggrecan gene in the presence or
absence of RA in TC6 cells were examined. TC6 cells were transfected with the AgCAT-8 construct and cultured in the absence or presence of 1
mM RA for 72 h. CAT activity was determined as described under “Materials and Methods.” The experiment was conducted in three independently
transfected cultures/group. Data are presented as means 6 S.D. (n 5 3).
FIG. 7. RA activates transcription via the Sry/Sox consensus sequence in TC6 cells. The transcriptional activity of the AACAAAG
concatamer-LUC reporter gene construct by RA in TC6 cells was examined. TC6 cells were cotransfected with 1 mg of reporter plasmid and cultured
in the absence or presence of 1 mM RA for 72 h. Experiments were repeated twice using six independently transfected cultures. Representative data
are shown. Data are presented as means 6 S.D. (n 5 6). *, p , 0.01 by unpaired Student’s t test.
FIG. 8. RA enhances the transcriptional activity of a reporter construct containing the type II procollagen gene enhancer in TC6
cells. The RA effect on the transcriptional activity of the pCII4-C-CAT (Col2-CAT) reporter construct containing the chondrocyte-specific Sry/Sox
consensus sequence within the enhancer region of the type II procollagen gene was examined. TC6 cells were transfected with 1 mg of reporter
plasmid and cultured in the absence or presence of 1 mM RA for 72 h. The pSV2-CAT plasmid was used as a positive control. The transfected cells
were incubated for 72 h. CAT activity was determined as described under “Materials and Methods.” Experiments were repeated twice in triplicate
with independent preparations of cell extracts. Representative data are shown. Data are presented as means 6 S.D. (n 5 3). *, p , 0.01 by unpaired
Student’s t test.
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dicts that binding site(s) of SOX9 would exist within the 4.5-kb
first intron fragment of the aggrecan gene. As support for this
prediction, we found that SOX9 transactivates gene expression
via the Sry/Sox consensus sequence in TC6 cells using a LUC
reporter construct that carries four tandem copies of a 30-mer
containing AACAAAG sequence derived from the enhancer
region of a gene encoding CD3-e, one of the T-cell antigen
receptor family (24).
In this study, SOX9 enhancement of aggrecan gene promoter
activity and SOX9 transactivation of gene expression via the
Sry/Sox consensus sequence were observed in the cartilage-
derived cell line TC6, but not in osteoblastic ROS17/2.8 cells. In
situ hybridization studies indicate that Sox9 is expressed in
cells that express cartilage-specific phenotype-related genes
such as aggrecan and the type II procollagen gene, but not in
bone and other connective tissues (7). This association of Sox9
expression and the aggrecan in in situ hybridization as well as
our present study suggest that SOX9 is active in a specific
cellular background. It is intriguing that SOX9 did not en-
hance, but suppressed gene transcription of the same reporter
gene in osteoblastic ROS17/2.8 cells. It has been known that
regulation of gene transcription is dependent on either tissue-
specific positive or negative cofactors that modulate the func-
tions of basic transcriptional machinery to render a variety of
transcriptional regulation. It is intriguing to suspect that SOX9
will be functional in association with particular set(s) of tran-
scriptional modulators in specific types of cells in different
tissues. In fact, cells that do not express the type II procollagen
gene such as those in genital ridges and a specific area in the
embryonic heart also express Sox9 (7). Sox9 is also highly
expressed in testicular Sertoli cells and is involved in differen-
tiation of male gonads (30, 31). It is likely that SOX9 contrib-
utes to the function of these cells by controlling expression of
diverse target genes. Kamachi et al. (32) proposed that the
HMG domain of Sox genes is not sufficient to form a stable
protein-DNA complex with SOX-binding DNA sequences by
itself and that SOX proteins require binding partner factors
unique to each SOX or SOX subfamily to achieve stable com-
plex formation with the target DNA, which leads to transcrip-
tional activation. Lefebvre et al. (33) suggested that in addition
to SOX9, L-SOX5 and SOX6 cooperate with each other in
expression of chondrocyte-specific genes.
The diversity in the SOX9-specific regulation may also be
dependent on the small difference in the sequences flanking
the Sry/Sox consensus motif. Bell et al. (6) reported that SOX9
fusion protein bound to the AACAAAG sequence derived from
the enhancer region of a CD3-e gene and that this complex was
supershifted by anti-SOX9 antibody. Mertin et al. (34) reported
that binding activity between SOX9 fusion protein and the
AGAACAAAGC sequence derived from the enhancer region of
CD3-e was half of the binding activity between SOX9 fusion
protein and the preferred DNA-binding site of SOX9 (AGAA-
CAATGG), which was identified using a random oligonucleo-
tide selection assay. Overall, a difference in SOX9 functions in
the background of TC6 versus ROS17/2.8 cells may be due to
such different sets of the partner factors, including L-SOX5,
SOX6, and/or as yet unknown cofactors.
Against our prediction, SOX9 slightly suppressed AgCAT-8
activity in primary chondrocytes (by 20%). These effects were
small although statistically significant (p , 0.05) and repro-
ducible in two independent experiments (Fig. 1B, lower panel).
We assume that this difference in the SOX9 regulation of
AgCAT-8 in TC6 cells versus primary chondrocytes could be
related to the difference in the endogenous levels of SOX9
expression. Northern blot analysis indicated that primary
chondrocytes express Sox9 mRNA at severalfold higher levels
than TC6 cells (data not shown). SOX9 overexpression en-
hanced AgCAT-8 activity in TC6 cells, possibly due to the low
SOX9 background in these cells, whereas SOX9 overexpression
FIG. 9. RA suppresses the proliferation of TC6 cells. TC6 cells
were seeded into four-well plates (2 cm2/well) and cultured in a-MEM
supplemented with 0.5% FBS in the absence or presence of RA. At the
indicated time points, the cells were trypsinized and counted five times
using Coulter counter. A, time course of the RA effects on cell number.
RA at 1 mM significantly reduced the number of TC6 cell after 2 and 3
days of treatment. B, dose dependence of the RA effect on cell prolifer-
ation. RA reduced TC6 cell numbers in a dose-dependent manner after
3 days of treatment. Experiments were repeated twice using four inde-
pendently treated cultures. Representative data are shown. Data are
presented as means 6 S.D. (n 5 4). *, p , 0.01 by unpaired Student’s t
test.
FIG. 10. SOX9 effect on alkaline phosphatase mRNA expres-
sion in ROS17/2.8 cells and primary osteoblasts. ROS17/2.8 cells
and primary osteoblasts were seeded into 10-cm plates, and confluent
ROS17/2.8 cells and primary osteoblasts were transfected with 10 mg of
empty pSG5 vector (2) or 10 mg of SOX9 expression vector (1) using 20
mg of LipofectAMINE. After transfected cells were incubated for 48 h,
total RNA was isolated and subjected to Northern blot analysis as
described under “Materials and Methods.” Sox9, alkaline phosphatase
(ALP), and GAPDH mRNAs are indicated.
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in the presence of high levels of SOX9 may be suppressive, as
competition against cofactors may exist.
Although SOX9 decreased AgCAT-8 transcriptional activity
by ;80% in ROS17/2.8 cells, SOX9 virtually did not affect
AgCAT-8 activity in primary osteoblasts. We could not detect
Sox9 mRNA expression by Northern blot analysis in either
ROS17/2.8 cells or primary osteoblasts. Therefore, diverse cel-
lular backgrounds (primary osteoblasts versus ROS17/12.8
cells) may affect AgCAT-8 activity differently in response to
SOX9 overexpression. Overall, certain differences exist be-
tween TC6 cells and primary chondrocytes with regard to the
SOX9 regulation of aggrecan gene expression, possibly due to
the diversities in cellular backgrounds that would include those
in the sets of transcription factors and cofactors.
RA plays an important role not only in pattern formation
during embryogenesis (35–37), but also in regulation of chon-
drocytes in cultures. RA treatment decreases expression of the
type II procollagen gene in primary chondrocytes (28, 38) and
suppresses the enhancer activity of pCII4-C reporter plasmid
containing the promoter and enhancer regions of the type II
procollagen gene in primary chondrocytes prepared from
sterna of day 15 chickens (20). In contrast, RA stimulated the
enhancer activity of the pCII4-C reporter plasmid in TC6 cells,
where RA enhanced mRNA levels of Sox9, which regulates the
type II procollagen gene directly (6, 27). This apparent diver-
sity in the responses to RA could be due to several possibilities.
For instance, responsiveness to RA may depend on chondrocyte
subtypes; however, primary chondrocytes consist of heteroge-
neous subpopulations. On the other hand, TC6 cells consist of
homogeneous population and represent one of the subpopula-
tions in chondrocytes at a certain stage, but not all. RA may
up-regulate chondrocytic phenotype-related genes such as Sox9
and type II procollagen in this subtype specifically. As another
possibility, the apparent dissociation of RA effects on the 1.6-kb
fragment of the type II collagen gene versus those on the
transcriptional activity of the 8-kb fragment of the aggrecan
gene in TC6 cells could be due to the diversities in the inter-
action of different sets of transcription factors that are binding
to their cognate DNA elements present in various combinations
within these two promoters.
Temperature shift experiments indicate that basal levels of
Sox9 expression and RA effects on its expression are similar
between 33 and 39 °C, whereas at 39 °C, SOX9 did not affect
AgCAT-8 activity in TC6 cells, in contrast to its enhancement
at 33 °C (data not shown). These observations reveal that both
a similarity and a difference exist between 33 and 39 °C cul-
tures of TC6 cells. Chondrocytes at different maturation stages
share certain common phenotypes, whereas chondrocytes at
each of the specific stages such as proliferating chondrocytes or
hypertrophic chondrocytes exhibit specific features. Our obser-
vations on the similarity and the difference between the TC6
cells cultured at 33 and 39 °C could represent these common
and specific features, respectively.
Altogether, we demonstrate in this study that SOX9 acti-
vates aggrecan promoter/enhancer transcription in TC6 cells.
Our results also suggest that RA enhances Sox9 expression
and, in turn, SOX9 transactivates the type II procollagen gene
via the Sry/Sox consensus sequence in TC6 cells.
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